Deciphera rises on GIST response data, proposes follow-on
Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) added $12.40 (48%) to $38.31 on Monday after reporting updated data from heavily pretreated patients with gastrointestinal stromal tumors who received the company's DCC-2618 in a Phase I trial. The data were presented Saturday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Monday's stock move translated to a gain in the company's market cap of over $400 million...
BCIQ Target Profiles
Platelet derived growth factor receptor (PDGFR)
Platelet derived growth factor receptor A (PDGFRA) (PDGFR2) (CD140A)
Stem cell factor (SCF) receptor tyrosine kinase (c-Kit) (KIT) (CD117)
Tyrosine kinase receptor 2 (Tie2)
Vascular endothelial growth factor (VEGF) receptor
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)